ATE525395T1 - Fusions proteine von glp-1-analoga - Google Patents

Fusions proteine von glp-1-analoga

Info

Publication number
ATE525395T1
ATE525395T1 AT04752589T AT04752589T ATE525395T1 AT E525395 T1 ATE525395 T1 AT E525395T1 AT 04752589 T AT04752589 T AT 04752589T AT 04752589 T AT04752589 T AT 04752589T AT E525395 T1 ATE525395 T1 AT E525395T1
Authority
AT
Austria
Prior art keywords
glp
analogs
fusion proteins
fusion
proteins
Prior art date
Application number
AT04752589T
Other languages
German (de)
English (en)
Inventor
Wolfgang Glaesner
Rohn Millican
Andrew Vick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE525395(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE525395T1 publication Critical patent/ATE525395T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04752589T 2003-06-12 2004-06-10 Fusions proteine von glp-1-analoga ATE525395T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47788003P 2003-06-12 2003-06-12
PCT/US2004/015595 WO2005000892A2 (en) 2003-06-12 2004-06-10 Glp-1 analog fusion plroteins

Publications (1)

Publication Number Publication Date
ATE525395T1 true ATE525395T1 (de) 2011-10-15

Family

ID=33551775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752589T ATE525395T1 (de) 2003-06-12 2004-06-10 Fusions proteine von glp-1-analoga

Country Status (28)

Country Link
US (2) US7452966B2 (OSRAM)
EP (2) EP2368909A1 (OSRAM)
JP (1) JP4629047B2 (OSRAM)
KR (1) KR100758755B1 (OSRAM)
CN (2) CN1802386B (OSRAM)
AR (1) AR044776A1 (OSRAM)
AT (1) ATE525395T1 (OSRAM)
AU (1) AU2004251145C1 (OSRAM)
BE (1) BE2015C007I2 (OSRAM)
BR (1) BRPI0411132B8 (OSRAM)
CA (1) CA2528591C (OSRAM)
CY (2) CY1111991T1 (OSRAM)
DK (1) DK1641823T3 (OSRAM)
EA (1) EA008831B1 (OSRAM)
ES (1) ES2371072T3 (OSRAM)
FR (1) FR15C0010I2 (OSRAM)
HR (1) HRP20110714T1 (OSRAM)
HU (1) HUS1500024I1 (OSRAM)
IL (1) IL171926A (OSRAM)
LT (1) LTC1641823I2 (OSRAM)
MX (1) MXPA05013565A (OSRAM)
NZ (1) NZ543292A (OSRAM)
PL (1) PL1641823T3 (OSRAM)
PT (1) PT1641823E (OSRAM)
SI (1) SI1641823T1 (OSRAM)
TW (1) TW200507870A (OSRAM)
UA (1) UA87458C2 (OSRAM)
WO (1) WO2005000892A2 (OSRAM)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6905688B2 (en) 2000-04-12 2005-06-14 Human Genome Sciences, Inc. Albumin fusion proteins
CN100423777C (zh) * 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
HRP20110714T1 (hr) * 2003-06-12 2011-11-30 Eli Lilly And Company Fuzijski proteini analoga glp-1
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
ATE435235T1 (de) * 2004-12-22 2009-07-15 Lilly Co Eli Formulierungen glp-1-analoger fusionsproteine
MX2007014052A (es) * 2005-05-13 2008-02-05 Lilly Co Eli Compuestos glp-1 pegilados.
CN101273134B (zh) * 2005-07-27 2012-01-04 王庆华 用于预防和治疗ⅰ型和ⅱ型糖尿病的组合物和方法
CN101277722A (zh) 2005-08-06 2008-10-01 王庆华 用于预防和治疗ⅰ型糖尿病的组合物及方法
EP1767545B1 (en) * 2005-09-22 2009-11-11 Biocompatibles UK Limited GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
KR20080071134A (ko) * 2005-10-24 2008-08-01 센토코 인코포레이티드 Ｇｌｐ-２ 모방체，폴리펩티드，조성물，방법 및 용도
SI1965823T1 (sl) 2005-11-04 2016-09-30 Glaxosmithkline Llc Corporation Service Company Postopki za dajanje hipoglikemičnih sredstev
ES2572952T3 (es) * 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
EP2076604A4 (en) * 2006-08-31 2009-09-02 Centocor Ortho Biotech Inc GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
CA2663047A1 (en) * 2006-09-06 2008-03-13 Phase Bioscience, Inc. Therapeutic elastin-like polypeptide (elp) fusion proteins
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
RU2477286C2 (ru) * 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2010518039A (ja) 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
CN101790538B (zh) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 胰高血糖素/glp-1受体共激动剂
EP2139509A2 (en) * 2007-03-15 2010-01-06 Biogen Idec MA, Inc. Treatment of autoimmune disorders
RU2539829C2 (ru) * 2007-06-19 2015-01-27 ГЛИТЕК,ИНК.,Япония Пептид glp-1 с присоединенной олигосахаридной цепью
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
EP2185178B1 (en) * 2007-08-03 2017-08-23 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP5771005B2 (ja) * 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP2011511778A (ja) * 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2009155257A1 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
PE20100056A1 (es) * 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
TWI474832B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 胰高血糖素／ｇｌｐ-１受體共同激動劑
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
UA105016C2 (uk) 2008-10-10 2014-04-10 Амген Інк. Fgf21 мутанти і їх застосування
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
LT3248610T (lt) 2009-05-05 2024-01-25 Amgen Inc. Fgf21 mutantai ir jų panaudojimas
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
EP2506861A1 (en) * 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
PH12012502018A1 (en) 2010-04-30 2018-03-21 Sanwa Kagaku Kenkyusho Co Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
BR112012028704A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glugagon da superfamília de peptídeos exibindo atividade do receptor com hormônio nuclear, pró fármaco, dímero ou multímero, composição farmacêutica que o compreendem e método de administração do mesmo.
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
CA2829037C (en) 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
HRP20181690T4 (hr) 2011-03-29 2025-01-03 Roche Glycart Ag Varijante protutijela fc
WO2012177444A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
CN103687878B (zh) 2011-07-22 2018-01-09 德国杰特贝林生物制品有限公司 抑制性的抗因子xii/xiia单克隆抗体及其用途
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
EP2780031B1 (en) 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
MX2014015558A (es) 2012-06-21 2015-03-05 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
DK3366705T5 (da) * 2012-09-12 2024-09-30 Genzyme Corp Fc-indeholdende polypeptider med ændret glycosylering og reduceret effektorfunktion
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
CN104870019A (zh) 2012-11-27 2015-08-26 阿特根公司 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物
MX367024B (es) 2012-11-27 2019-08-02 Biomarin Pharm Inc Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
SG11201506088RA (en) 2013-03-11 2015-09-29 Genzyme Corp Hyperglycosylated binding polypeptides
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
PL3013366T3 (pl) 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN104592381A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种利拉鲁肽中间体多肽的制备方法
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
SI3129067T1 (sl) 2014-03-19 2023-06-30 Genzyme Corporation Za mesto specifičen glikoinženiring tarčnih deležev
SG11201608120TA (en) * 2014-03-31 2016-11-29 Hanmi Pharm Ind Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
CN106456778A (zh) 2014-06-18 2017-02-22 德国杰特贝林生物制品有限公司 在神经创伤性病患中使用因子xii抑制剂进行治疗
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
EA038361B1 (ru) 2014-07-21 2021-08-13 Делиниа, Инк. Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
KR20170035910A (ko) 2014-08-11 2017-03-31 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
CN104293834B (zh) * 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
TWI708781B (zh) 2014-12-23 2020-11-01 丹麥商諾佛 儂迪克股份有限公司 Fgf21衍生物及其用途
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
IL296682A (en) 2015-12-23 2022-11-01 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
CN108779165B (zh) 2016-01-07 2022-12-02 康诺贝林伦瑙有限公司 突变的冯·维勒布兰德因子
ES2909573T3 (es) 2016-01-07 2022-05-09 CSL Behring Lengnau AG Factor de von Willebrand truncado mutado
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3019851A1 (en) 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING SAME
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
AU2017359172A1 (en) 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
KR102692516B1 (ko) 2016-11-10 2024-08-08 주식회사유한양행 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
CN110381986B (zh) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
EP3351262A1 (en) 2016-12-30 2018-07-25 Istanbul Universitesi Rektorlugu Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EP3596130B1 (en) 2017-03-14 2024-12-04 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.
EP4279925A3 (en) * 2017-06-01 2024-01-24 Eli Lilly and Company Dulaglutide for the treatment of chronic kidney disease
BR112019026743A2 (pt) 2017-06-22 2020-06-30 CSL Behring Lengnau AG modulação da imunogenicidade de fviii através de vwf truncado
CA3071337A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CA3073964A1 (en) 2017-09-22 2019-03-28 Regeneron Pharmaceuticals, Inc. Glucagon-like peptide 1 receptor agonists and uses thereof
KR20220146656A (ko) 2017-11-21 2022-11-01 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
US11752173B2 (en) 2017-12-19 2023-09-12 Beijing Jiyuan Biological Technology Co., Ltd. FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
WO2019125003A1 (ko) * 2017-12-22 2019-06-27 케이비바이오메드 주식회사 경구용 유전자 전달체 및 이의 용도
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN110128525B (zh) 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
CN112912095A (zh) 2018-07-19 2021-06-04 D&D制药技术股份有限公司 包括多肽的药物组合物
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
CN110878127B (zh) 2018-09-06 2022-06-28 浙江柏拉阿图医药科技有限公司 长效重组GLP1-Fc-CD47蛋白及其制备和用途
ES3011982T3 (en) 2018-10-22 2025-04-08 Janssen Sciences Ireland Unlimited Co Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN111234000B (zh) * 2018-11-28 2023-05-26 鲁南制药集团股份有限公司 艾塞纳肽类似物
CN111269312B (zh) * 2018-12-04 2023-05-09 鲁南制药集团股份有限公司 一种异源融合蛋白质
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
AU2020230668B2 (en) * 2019-03-05 2025-05-29 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
WO2020185533A1 (en) 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy
JP7728176B2 (ja) * 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
US12365734B2 (en) 2019-04-03 2025-07-22 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
CA3136969A1 (en) * 2019-04-23 2020-10-29 Lg Chem, Ltd. Fusion polypeptide comprising fc region of immunoglobulin and gdf15
EP3968988A1 (en) 2019-05-17 2022-03-23 Universität Zürich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN116438312A (zh) 2020-08-24 2023-07-14 宾夕法尼亚州大学信托人 编码glp-1受体激动剂融合物的病毒载体和其在治疗代谢性疾病中的用途
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
CN116568327A (zh) 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法
CN114685644A (zh) 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
WO2022162218A1 (en) 2021-02-01 2022-08-04 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
CA3217518A1 (en) 2021-05-07 2022-11-10 Rebecca Butcher Expression system for producing a recombinant haptoglobin (hp) beta chain
KR20240029769A (ko) 2021-07-06 2024-03-06 수조우 알파맵 씨오., 엘티디. 융합단백질 및 이의 응용
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados
CN114774496B (zh) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 一种高密度发酵制备glp-1类似物的方法
AU2023332194A1 (en) 2022-09-02 2025-02-20 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
AU2023347206A1 (en) 2022-09-21 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
TW202421654A (zh) 2022-09-28 2024-06-01 丹麥商西蘭製藥公司 治療肥胖之方法
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024132147A1 (en) 2022-12-22 2024-06-27 Lifearc Galanin-2 receptor agonists
US20240318221A1 (en) 2023-03-23 2024-09-26 Eli Lilly And Company Methods of producing fc-containing proteins
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025122835A2 (en) 2023-12-08 2025-06-12 Eli Lilly And Company Methods of producing fc-containing proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0394538B1 (en) 1989-04-28 1996-10-16 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh A yeast cell of the genus schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
DE69334100T2 (de) * 1992-11-13 2007-07-19 Immunex Corp., Seattle Elk ligand, ein cytokin
AU3382595A (en) * 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DE69911975T2 (de) 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
DE60124710T2 (de) 2000-06-16 2007-09-13 Eli Lilly And Co., Indianapolis Analoge des glucagon ähnlichen peptid-1
US7271149B2 (en) 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
ES2425738T3 (es) * 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
HRP20110714T1 (hr) * 2003-06-12 2011-11-30 Eli Lilly And Company Fuzijski proteini analoga glp-1

Also Published As

Publication number Publication date
EA008831B1 (ru) 2007-08-31
IL171926A (en) 2010-12-30
US8273854B2 (en) 2012-09-25
JP2007536902A (ja) 2007-12-20
HUS1500024I1 (hu) 2017-04-28
WO2005000892A3 (en) 2005-03-03
AU2004251145B2 (en) 2010-09-09
UA87458C2 (ru) 2009-07-27
DK1641823T3 (da) 2011-12-12
EP2368909A1 (en) 2011-09-28
TW200507870A (en) 2005-03-01
HRP20110714T1 (hr) 2011-11-30
AU2004251145A1 (en) 2005-01-06
BRPI0411132B8 (pt) 2021-05-25
WO2005000892A2 (en) 2005-01-06
FR15C0010I2 (fr) 2015-07-24
CA2528591A1 (en) 2005-01-06
BE2015C007I2 (OSRAM) 2023-08-09
CA2528591C (en) 2013-01-08
MXPA05013565A (es) 2006-03-09
CN1802386B (zh) 2010-12-15
JP4629047B2 (ja) 2011-02-09
CN1802386A (zh) 2006-07-12
ES2371072T3 (es) 2011-12-27
NZ543292A (en) 2008-04-30
CY2015002I1 (el) 2015-11-04
AU2004251145C1 (en) 2011-04-14
IL171926A0 (en) 2006-04-10
FR15C0010I1 (OSRAM) 2015-03-13
EP1641823A2 (en) 2006-04-05
LTPA2015007I1 (lt) 2015-03-25
HK1149566A1 (en) 2011-10-07
PT1641823E (pt) 2011-11-08
BRPI0411132A (pt) 2006-07-18
SI1641823T1 (sl) 2011-12-30
KR100758755B1 (ko) 2007-09-14
LTC1641823I2 (lt) 2016-12-12
BRPI0411132B1 (pt) 2016-12-13
CY2015002I2 (el) 2017-04-05
AR044776A1 (es) 2005-10-05
US20090074769A1 (en) 2009-03-19
CN101974090B (zh) 2015-06-17
US7452966B2 (en) 2008-11-18
CN101974090A (zh) 2011-02-16
KR20060022262A (ko) 2006-03-09
US20070036806A1 (en) 2007-02-15
CY1111991T1 (el) 2015-11-04
EP1641823B1 (en) 2011-09-21
EA200600015A1 (ru) 2006-06-30
PL1641823T3 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
ATE525395T1 (de) Fusions proteine von glp-1-analoga
EP1490094A4 (en) ANTIBODY FUSION PROTEINS AS EFFECTIVE ADJUVANTS FOR PROTEIN VACCINATION
DK2236152T3 (da) Albuminfusionsproteiner
DK1463751T3 (da) Albuminfusionsproteiner.
EP1503785A4 (en) NEW THROMBOMODULIN FUSION PROTEINS AGAINST THE TISSUE FACTOR AS ANTICOAGULANTS
MA29067B1 (fr) Protéines de fusion de RAGE et méthodes d'utilisation
CY2013025I1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
DE60325892D1 (de) Stellungs- und verwendungsverfahren
DE60326874D1 (de) Neue verwendung von erythropoietin in herzerkrankungen
DK1567112T3 (da) Thiazolidin-4-oner til at hæmme hYAK3-proteiner
DK1781802T3 (da) Fremstilling af et TNFR-Ig-fusionsprotein
IL206518A0 (en) HETERODIMERIC FOLLICLE STIMULATING HORMONE - Fc (FSH-Fc) FUSION PROTEINS
DE60332711D1 (de) Neue insektizide proteine von bazillus thuringiensis
ATE515269T1 (de) Gag-bindende proteine
ATE309789T1 (de) Darreichungsform von ibuprofen-natrium
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
DK1678297T3 (da) Fremgangsmåde til fremstilling af Gamma-carboxylerede proteiner
NO20021275D0 (no) Transgent produserte fusjonsproteiner
DE602004013557D1 (de) FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
EP1670428A4 (en) HYBRID PROTEINS G-CSF-TRANSFERRIN
DE60040524D1 (de) Intein-vermittelte ligation von exprimierten proteinen
NO20042429L (no) Nye immunogene etterlikninger av multimere proteiner
DE69823225D1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
DE60330315D1 (de) Acylfluorid-aktivierung von mit carboxysilyl beschichteten glassubstraten
DE10082298D2 (de) Chimäre Proteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1641823

Country of ref document: EP